• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从非随机检测数据估计人群感染率:来自 COVID-19 大流行的证据。

Estimating population infection rates from non-random testing data: Evidence from the COVID-19 pandemic.

机构信息

Department of Applied Economics, HEC Montréal, Quebec, Canada.

Department of Economics, Université de Montréal, Quebec, Canada.

出版信息

PLoS One. 2024 Sep 26;19(9):e0311001. doi: 10.1371/journal.pone.0311001. eCollection 2024.

DOI:10.1371/journal.pone.0311001
PMID:39325815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11426536/
Abstract

To effectively respond to an emerging infectious disease outbreak, policymakers need timely and accurate measures of disease prevalence in the general population. This paper presents a new methodology to estimate real-time population infection rates from non-random testing data. The approach compares how the observed positivity rate varies with the size of the tested population and applies this gradient to infer total population infections. Applying this methodology to daily testing data across U.S. states during the first wave of the COVID-19 pandemic, we estimated widespread undiagnosed COVID-19 infections. Nationwide, we found that for every identified case, there were 12 population infections. Our prevalence estimates align with results from seroprevalence surveys, alternate approaches to measuring COVID-19 infections, and total excess mortality during the first wave of the pandemic.

摘要

为了有效应对新发传染病的爆发,政策制定者需要及时、准确地掌握一般人群中疾病的流行情况。本文提出了一种新的方法,可利用非随机检测数据来估算实时人群感染率。该方法通过比较观察到的阳性率随检测人群规模的变化,并利用这种梯度来推断总人群感染率。将该方法应用于美国 COVID-19 大流行第一波期间各州的每日检测数据,我们估算出广泛存在的未确诊 COVID-19 感染病例。在全国范围内,我们发现每确诊一例病例,就有 12 例人群感染。我们的流行率估计与血清流行率调查、衡量 COVID-19 感染的替代方法以及大流行第一波期间的总超额死亡率的结果一致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/28f52218b55d/pone.0311001.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/b88932eab675/pone.0311001.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/7af3eba69893/pone.0311001.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/b8599694fad8/pone.0311001.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/1942cd5f2d74/pone.0311001.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/28f52218b55d/pone.0311001.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/b88932eab675/pone.0311001.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/7af3eba69893/pone.0311001.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/b8599694fad8/pone.0311001.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/1942cd5f2d74/pone.0311001.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f498/11426536/28f52218b55d/pone.0311001.g005.jpg

相似文献

1
Estimating population infection rates from non-random testing data: Evidence from the COVID-19 pandemic.从非随机检测数据估计人群感染率:来自 COVID-19 大流行的证据。
PLoS One. 2024 Sep 26;19(9):e0311001. doi: 10.1371/journal.pone.0311001. eCollection 2024.
2
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.估算 2021 年 11 月 14 日前全球、区域和国家的 SARS-CoV-2 日感染和累计感染人数:一项统计分析。
Lancet. 2022 Jun 25;399(10344):2351-2380. doi: 10.1016/S0140-6736(22)00484-6. Epub 2022 Apr 8.
3
Using test positivity and reported case rates to estimate state-level COVID-19 prevalence and seroprevalence in the United States.利用检测阳性率和报告病例率来估计美国各州的 COVID-19 流行率和血清流行率。
PLoS Comput Biol. 2021 Sep 7;17(9):e1009374. doi: 10.1371/journal.pcbi.1009374. eCollection 2021 Sep.
4
Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.利用血清流行率调查估计美国 SARS-CoV-2 感染、有症状感染、住院和死亡人数。
JAMA Netw Open. 2021 Jan 4;4(1):e2033706. doi: 10.1001/jamanetworkopen.2020.33706.
5
Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.香港 3 波新冠疫情期间不明 SARS-CoV-2 感染的血清流行率。
JAMA Netw Open. 2021 Nov 1;4(11):e2132923. doi: 10.1001/jamanetworkopen.2021.32923.
6
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.伊朗 18 个城市一般人群和高风险职业人群中 SARS-CoV-2 抗体血清流行率:一项基于人群的横断面研究。
Lancet Infect Dis. 2021 Apr;21(4):473-481. doi: 10.1016/S1473-3099(20)30858-6. Epub 2020 Dec 15.
7
High-Throughput Multiplex SARS-CoV-2 IgG Microsphere Immunoassay for Dried Blood Spots: A Public Health Strategy for Enhanced Serosurvey Capacity.高通量多重 SARS-CoV-2 IgG 微球免疫分析检测干血斑:增强血清学调查能力的公共卫生策略。
Microbiol Spectr. 2021 Sep 3;9(1):e0013421. doi: 10.1128/Spectrum.00134-21. Epub 2021 Jul 28.
8
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.204 个国家和地区及 811 个次国家级行政单位 1950 年至 2021 年的全球年龄、性别特异性死亡率、预期寿命和人口估计,以及 COVID-19 大流行的影响:2021 年全球疾病负担研究的综合人口分析。
Lancet. 2024 May 18;403(10440):1989-2056. doi: 10.1016/S0140-6736(24)00476-8. Epub 2024 Mar 11.
9
Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave.在疫情高峰期间,米兰最大儿童医院的医护人员中新冠病毒感染的血清阳性率较低。
Infect Control Hosp Epidemiol. 2020 Dec;41(12):1468-1469. doi: 10.1017/ice.2020.401. Epub 2020 Aug 6.
10
An indirect method to monitor the fraction of people ever infected with COVID-19: An application to the United States.一种监测人群中 COVID-19 既往感染比例的间接方法:在美国的应用。
PLoS One. 2021 Jan 28;16(1):e0245845. doi: 10.1371/journal.pone.0245845. eCollection 2021.

本文引用的文献

1
Estimates of COVID-19 Cases across Four Canadian Provinces.加拿大四个省份的新冠病毒病病例估计数。
Can Public Policy. 2020 Oct 7;46(Suppl 3):S203-S216. doi: 10.3138/cpp.2020-035.
2
Identification of the first COVID-19 infections in the US using a retrospective analysis (REMEDID).使用回顾性分析(REMEDID)鉴定美国的首例 COVID-19 感染。
Spat Spatiotemporal Epidemiol. 2022 Aug;42:100517. doi: 10.1016/j.sste.2022.100517. Epub 2022 May 10.
3
Emergence of an early SARS-CoV-2 epidemic in the United States.美国出现早期新冠病毒疫情。
Cell. 2021 Sep 16;184(19):4939-4952.e15. doi: 10.1016/j.cell.2021.07.030. Epub 2021 Jul 27.
4
A comparison of 2020 health policy responses to the COVID-19 pandemic in Canada, Ireland, the United Kingdom and the United States of America.加拿大、爱尔兰、英国和美国 2020 年应对 COVID-19 大流行的卫生政策比较。
Health Policy. 2022 May;126(5):427-437. doi: 10.1016/j.healthpol.2021.06.012. Epub 2021 Jul 1.
5
Retrospective methodology to estimate daily infections from deaths (REMEDID) in COVID-19: the Spain case study.回顾性方法估计 COVID-19 死亡病例中的日感染人数(REMEDID):西班牙案例研究。
Sci Rep. 2021 May 28;11(1):11274. doi: 10.1038/s41598-021-90051-7.
6
Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis.无症状 COVID-19 病例在整个感染过程中的严重程度:系统评价和荟萃分析。
PLoS One. 2021 Mar 23;16(3):e0249090. doi: 10.1371/journal.pone.0249090. eCollection 2021.
7
Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence.冠状病毒的繁殖数:基于全球水平证据的系统评价和荟萃分析。
PLoS One. 2020 Nov 11;15(11):e0242128. doi: 10.1371/journal.pone.0242128. eCollection 2020.
8
Differential effects of intervention timing on COVID-19 spread in the United States.干预时机对美国 COVID-19 传播的影响差异。
Sci Adv. 2020 Dec 4;6(49). doi: 10.1126/sciadv.abd6370. Print 2020 Dec.
9
Explaining among-country variation in COVID-19 case fatality rate.解释 COVID-19 病死率的国家间差异。
Sci Rep. 2020 Nov 3;10(1):18909. doi: 10.1038/s41598-020-75848-2.
10
Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City region.测序确定了 SARS-CoV-2 多次早期传入纽约地区。
Genome Res. 2020 Dec;30(12):1781-1788. doi: 10.1101/gr.266676.120. Epub 2020 Oct 22.